181 Views

Navigating MET Aberrations in NSCLC: Implications for Pathologists, Oncologists, and for Targeted Therapies

Wednesday, November 12, 2025

10:00 AM - 10:50 AM EST

Location: 151AB, Level 1

Corporate Workshop Panelist(s)

Michelle Shiller, DO, AP/CP, MGP

Co-Director Cancer Genetics
Baylor Scott & White Health
Dallas, Texas, United States
FK

Farah Khalil, MD

Anatomical Pathologist
Moffit Cancer Center, Tampa Florida
DS

Dr. Michael R Shafique

Assistant Professor Thoracic Oncology
Moffit Cancer Center, Tampa Florida

Panel presentation and discussion between a Medical Oncologist, Pulmonologist and Molecular Pathologist to:
-Understand patient populations affected by MET aberrations
-Identify and discuss different types of MET aberrations in NSCLC
-Explore therapy decisions related to MET aberrations
-Discuss various testing methodologies for MET aberrations
-Understand MET protein overexpression as a test and a target for therapy